Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research shows how IL-22 interacts with KRAS mutant tumours to promote excessive growth in colorectal cancer

Cancer attacking a cell in the colon © Shutterstock

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth leading cause of cancer-related deaths. For patients, current therapy primarily entails surgical removal of the tumour and chemotherapy, to which tumours are variably responsive.

The immune system can be a double-edged sword in cancer because it can both combat and contribute to tumour development. The Powrie Group at the Kennedy Institute of Rheumatology were interested understanding the role of molecule IL-22, produced by immune cells, and to identify mechanisms by which it might influence CRC.

Their research published in Clinical Cancer Research found a link between the receptor for IL-22 and a mutation in the gene KRAS, showing that they work cooperatively to promote excessive growth and division of tumour cells. This is hypothesised to explain why prognosis is significantly worse for patients whose tumours have both a mutation in KRAS and high expression of the IL-22 receptor.

"IL-22 is critical in maintaining immune homeostasis by triggering the release of anti-microbial substances and the healthy turnover of the cells that line the gut," said Beth Mann, Postdoc Researcher in Gut T Cell Regulation at the Kennedy Institute for Rheumatology, University of Oxford. "Nonetheless, there is growing evidence that IL-22 can be detrimental by promoting excessive proliferation of tumour cells. We have shown this to be particularly true for cancer cells that have a mutation in the gene KRAS, which is present in 40-45% of colorectal tumours."

KRAS-mutant tumours are particularly poorly responsive to certain standard therapies and despite considerable efforts, the development of KRAS inhibitors has been largely unsuccessful. These latest results mean that for patients whose tumours have a KRAS mutation and high amounts of IL-22 receptor closer monitoring and more aggressive or alternative therapy strategies (like blocking IL-22) may be beneficial.

The research was primarily funded by an 'Experimental Medicine Challenge Grant' from the MRC and CRUK Grand Challenge funding (OPTIMISTICC).

Similar stories

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.

Building a humanoid bioreactor

A humanoid robot is being used at NDORMS in an attempt to grow tendon tissue for repairing shoulder injuries.

Professor Fiona Powrie recognised in Queen’s Birthday Honours

Professor Fiona Powrie was honoured in the 2022 Queen’s Birthday Honours List, published as Her Majesty celebrates her Platinum Jubilee.